Purpose: This study aimed to investigate the prognostic
significance of the Family with Sequence Similarity 72 member (FAM72) gene
family in clear cell renal carcinoma (ccRCC) using a bioinformatic approach.
Background: The Family with Sequence Similarity 72 (FAM72)
gene family, specific to neural stem cells, has emerged as a potential
biomarker in various cancers, including glioblastoma multiforme, adrenocortical
carcinoma, and lung adenocarcinoma.
Methods: We conducted an analysis of FAM72 expression levels
in ccRCC tissues and normal kidney tissues using TCGA data. We performed
univariate and multivariate Cox regression analysis to assess the prognostic
value of FAM72 expression. Furthermore, to find enriched biological processes
connected to FAM72 expression, Gene Ontology (GO) and Gene Set Enrichment
Analysis (GSEA) were used. We also examined the degree of methylation and
immune cell infiltration in patients with ccRCC.
Results: Our bioinformatic analysis revealed that FAM72
expression levels were significantly higher in ccRCC tissues than in normal
kidney tissues. High expression of FAM72 was associated with poor prognosis in
ccRCC patients and was found to be an independent prognostic factor for ccRCC.
GO and GSEA analyses indicated that FAM72 was enriched in biological processes
related to mitosis, cell cycle, and DNA metabolism. Moreover, a significant
correlation was found between FAM72 and immune cell infiltration and the level
of methylation in ccRCC patients.
Conclusion: Our findings suggest that FAM72 could serve as
an unfavorable prognostic molecular marker for ccRCC. A comprehensive
understanding of FAM72 could provide crucial insights into tumor progression
and prognosis. The results not only contribute to the understanding of FAM72's
role in ccRCC but also pave the way for future research aimed at exploring the
therapeutic potential of targeting the FAM72 gene family. The development of
targeted therapies that modulate FAM72 expression or function could offer a
novel approach to improving treatment outcomes for ccRCC patients.
Author(s) Details:
Hui Gou,
Department of Pharmacy, The Affiliated Hospital of Southwest Medical
University, Luzhou-646000, China.
Ping Chen
Department of Pharmacy, The Affiliated Hospital of Southwest Medical
University, Luzhou-646000, China.
Wenbing Wu
Department of Biochemistry and Molecular Biology, School of Basic Medical
Sciences, Southwest Medical University, Luzhou-646000, China.
Please see the link here: https://doi.org/10.9734/bpi/rdcbr/v3/8471E
No comments:
Post a Comment